Skip to main content
logo
AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
5.48
-0.19 (-3.35%)
Jul 24, 2026, 1:23 PM EDT - Market open

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
Research Fees Revenue
31.26M27.21M26.28M
Research Fees Revenue Growth
14.91%3.52%-26.08%
Milestone Payments Revenue
-1.00M1.50M
Milestone Payments Revenue Growth
--33.33%-
Licensing and Royalty Revenue
46.94M46.92M1.05M
Licensing and Royalty Revenue Growth
0.05%4372.83%8.26%
Revenue (Other)
1.00M--
Revenue (Total)
79.21M75.13M28.83M
Revenue (Total) Growth
5.43%160.56%-24.17%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18
In the Clinic - Partner-Led Programs with Downstreams
5.005.00-
Preclinical Development - Partner-Led Programs with Downstreams
35.0039.00-
Preclinical Development - Partner-Led Programs with Downstreams Growth
-10.26%--
Total Partner-Led Programs with Downstreams
40.0044.00-
Total Partner-Led Programs with Downstreams Growth
-9.09%--
Molecules in the Clinic with Downstreams
14.0014.00-
Cummulative Number of Partner-Initiated Program Starts with Downstreams
-104.0096.00
Cummulative Number of Partner-Initiated Program Starts with Downstreams Growth
-8.33%10.35%
Partner-Led - Cummulative Number of Molecules In the Clinic
-17.00-
AbCellera-Led - Cummulative Number of Molecules In the Clinic
-2.00-
Total Cummulative Number of Molecules In the Clinic
-19.0016.00
Total Cummulative Number of Molecules In the Clinic Growth
-18.75%23.08%